Literature DB >> 1886510

[Ferritin in acute leukemia. Serum ferritin concentration as a nonspecific tumor marker for M1 and M2 myeloid leukemia].

E Aulbert1, H Fromm, H Hornemann.   

Abstract

Serum ferritin concentration was studied in 136 patients with different types of acute leukemia. Pretreatment serum ferritin concentrations in the immature myeloblastic leukemia (M1 and M2 of the FAB-classification of acute leukemias) was found to be highly increased compared to the more mature types of acute myeloblastic leukemias (M3 to M5) and the acute lymphoblastic leukemias (L1 to L3). Investigation of the intracellular ferritin concentration showed, that the serum ferritin levels paralleled the intracellular ferritin concentration within the leukemic blasts. Within the immature myeloic blasts (M1) the intracellular ferritin concentration was 14-fold increased compared to normal granulocytes. This correlated with the 17-fold increased serum ferritin levels in these patients. Intracellular ferritin concentrations within the leukemic blasts of more mature types of acute leukemia (M3 to M5) were found to be only slightly increased. These data support the concept, that an increased synthesis and release of ferritin by the leukemic blasts is responsible for the increased serum ferritin concentration. This concept is also supported by the observation, that a further increase of serum ferritin concentration was seen during a cytotoxic chemotherapy. It is noteworthy, that this increase was more pronounced in the immature leukemias obviously caused by a loss of intracellular ferritin from the damaged leukemic blasts. The serum ferritin levels followed closely the activity of the disease. Increased pretreatment serum ferritin concentrations normalized completely when patients achieved complete remission. In contrast, in patients with tumor relapse or tumor progression serum ferritin concentrations increased again. These data suggest that the serum ferritin in immature myeloblastic leukemia has the characteristics of a tumor associated marker.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886510

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  4 in total

1.  Poor prognostic impact of high serum ferritin levels in patients with a lower risk of diffuse large B cell lymphoma.

Authors:  Da Jung Kim; Taeyun Kim; Jee-Yeong Jeong; Jae-Cheol Jo; Won Sik Lee; Ho-Jin Shin; Ji Hyun Lee; Ho Sup Lee
Journal:  Int J Hematol       Date:  2020-01-06       Impact factor: 2.490

2.  A dual-label time-resolved fluorescence immunoassay for the simultaneous determination of ferritin and β2 -microglobulin.

Authors:  Zhi Liu; Jing Huang; Rui-Ming Ou; Meng-Dong Yao; Yan-Lin She; Rui Chen; Cheng Li; Li Xu; Aikebaier Abudureyimu; Qing Zhang; Shuang Liu
Journal:  J Clin Lab Anal       Date:  2017-02-23       Impact factor: 2.352

3.  Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma.

Authors:  Pınar Cömert; Abdulkerim Yıldız; Murat Yıldırım; Hacer Berna Afacan Öztürk; Çiğdem Pala; Murat Albayrak; Meltem Aylı
Journal:  Indian J Hematol Blood Transfus       Date:  2019-08-06       Impact factor: 0.900

4.  Iron metabolism and fungal infections in patients with haematological malignancies.

Authors:  C Iglesias-Osma; L Gonzalez-Villaron; J F San Miguel; M D Caballero; L Vazquez; S de Castro
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.